ATE82499T1 - Okulare hypotensivagenzien. - Google Patents

Okulare hypotensivagenzien.

Info

Publication number
ATE82499T1
ATE82499T1 AT88308299T AT88308299T ATE82499T1 AT E82499 T1 ATE82499 T1 AT E82499T1 AT 88308299 T AT88308299 T AT 88308299T AT 88308299 T AT88308299 T AT 88308299T AT E82499 T1 ATE82499 T1 AT E82499T1
Authority
AT
Austria
Prior art keywords
hypotensive agents
ocular hypotensive
ocular
show
agents
Prior art date
Application number
AT88308299T
Other languages
German (de)
English (en)
Inventor
Ryuzo Ueno
Ryuji Ueno
Tomio Oda
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26532381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE82499(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Application granted granted Critical
Publication of ATE82499T1 publication Critical patent/ATE82499T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT88308299T 1987-09-18 1988-09-08 Okulare hypotensivagenzien. ATE82499T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23589087 1987-09-18
JP33403787 1987-12-29
EP88308299A EP0308135B1 (en) 1987-09-18 1988-09-08 Ocular hypotensive agents

Publications (1)

Publication Number Publication Date
ATE82499T1 true ATE82499T1 (de) 1992-12-15

Family

ID=26532381

Family Applications (2)

Application Number Title Priority Date Filing Date
AT88308299T ATE82499T1 (de) 1987-09-18 1988-09-08 Okulare hypotensivagenzien.
AT91108317T ATE108330T1 (de) 1987-09-18 1988-09-08 Hypotensive okulare mittel.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT91108317T ATE108330T1 (de) 1987-09-18 1988-09-08 Hypotensive okulare mittel.

Country Status (11)

Country Link
US (1) US5001153A (enExample)
EP (2) EP0455264B1 (enExample)
JP (2) JPH02108A (enExample)
KR (1) KR930000051B1 (enExample)
AT (2) ATE82499T1 (enExample)
CA (1) CA1328075C (enExample)
DE (2) DE3876050T2 (enExample)
ES (1) ES2052735T3 (enExample)
GB (1) GB2209939B (enExample)
GR (1) GR3006319T3 (enExample)
NZ (1) NZ226197A (enExample)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
JP2597629B2 (ja) 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
ES2213504T1 (es) * 1988-09-06 2004-09-01 Pfizer Health Ab Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP1300149A3 (en) * 1988-09-06 2003-05-14 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
EP0580268B1 (en) * 1988-10-01 1998-01-14 R-Tech Ueno Ltd. Ocular hypotensive agents
EP0410652B1 (en) * 1989-07-27 1995-05-17 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Use of 15-keto-prostanoic acid derivatives in the manufacture of a medicament for improvement of excretion of potassium ion
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
ATE121624T1 (de) * 1989-08-09 1995-05-15 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von prostansäurederivaten zur herstellung von arzneimitteln zur verbesserung der ausscheidung von nichtprotein in die därme.
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
KR100224951B1 (ko) * 1990-03-08 1999-10-15 시오노 요시히코 15-데옥시프로스타글란딘유도체
CA2039420C (en) * 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
US5166175A (en) * 1990-05-22 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of ocular hypertension with a synergistic combination
DK0458588T3 (da) * 1990-05-22 1995-03-13 R Tech Ueno Ltd Behandling af okulær hypertension med en synergistisk kombination til okulær administration
ATE117208T1 (de) * 1990-05-22 1995-02-15 R Tech Ueno Ltd Behandlung von intraokularem druck mit einer ophthalmischen synergistischen kombination.
EP0458587B1 (en) * 1990-05-22 1993-07-14 R-Tech Ueno Ltd. Synergistic combination for ophthalmic use
US5175189A (en) * 1990-05-22 1992-12-29 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of ocular hypertension with a synergistic combination for ophthalmic use
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5270049A (en) * 1990-11-09 1993-12-14 Allergan, Inc. 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
US5139491A (en) * 1990-12-06 1992-08-18 Allergan, Inc. 2-decarboxyl-2-alkoxyalkyl prostaglandins as ocular hypotensives
TW210287B (enExample) * 1991-03-01 1993-08-01 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
US5221690A (en) * 1991-10-02 1993-06-22 R-Tech Ueno Ltd. Increasing the choroidal blood flow
EP0668076B1 (en) * 1992-08-26 2002-09-04 Sucampo AG Stabilization of a prostanoic acid compound
FR2707295A1 (fr) * 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5387608A (en) * 1993-08-17 1995-02-07 Allergan, Inc. Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents
JP2769294B2 (ja) * 1993-12-15 1998-06-25 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物及びそのためのプロスタグランジン化合物
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
WO1998021181A2 (en) * 1996-11-12 1998-05-22 Alcon Laboratories, Inc. 15-fluoro prostaglandins as ocular hypotensives
US6680339B2 (en) 1996-11-12 2004-01-20 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
AU5439398A (en) 1996-11-12 1998-06-03 Alcon Laboratories, Inc. Cis-delta4 analogs of prostaglandins as ocular hypotensives
DE69823852T2 (de) 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
WO1998039293A2 (en) 1997-03-07 1998-09-11 Alcon Laboratories, Inc. 13-thia prostaglandins for use in glaucoma therapy
US6770675B2 (en) 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
ATE326972T1 (de) 1997-10-13 2006-06-15 R Tech Ueno Ltd Heilende zusammensetzung für intraokulare hypertension oder glaukom
US6156785A (en) * 1998-01-23 2000-12-05 Merck Sharp & Dohme B.V. Method for increasing oxygen tension in the optic nerve and retina
US6096783A (en) * 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
JP5011548B2 (ja) * 1998-12-25 2012-08-29 株式会社アールテック・ウエノ 高眼圧症あるいは緑内障の処置用医薬組成物
SE9900672D0 (sv) 1999-02-25 1999-02-25 Synphora Ab Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
NZ513825A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
TWI225398B (en) 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
US6576663B2 (en) 1999-12-22 2003-06-10 Alcon, Inc. 6-Keto prostaglandin F1α and analogs for treating dry eye
US6545036B2 (en) 2000-01-18 2003-04-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US6548535B2 (en) 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
HUP0300391A3 (en) * 2000-03-16 2008-05-28 Sucampo Ag Use of prostaglandin related compounds for preparation of composition for use in treatment of ocular hypertension and glaucoma
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
AU2001239551B8 (en) 2000-03-24 2005-11-24 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
US6414021B1 (en) * 2000-08-25 2002-07-02 Sucampo Ag Control of intraocular pressure during surgery
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
US6291522B1 (en) * 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20050124595A1 (en) * 2002-03-15 2005-06-09 Goetz Michael A. Compositions and methods for treating glaucoma and ocular hypertension
EP1513523A1 (en) * 2002-06-06 2005-03-16 Merck Frosst Canada & Co. 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
JP2005532363A (ja) * 2002-06-14 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧を治療するための眼用組成物
CA2488884A1 (en) * 2002-06-17 2003-12-24 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
WO2003105781A2 (en) * 2002-06-17 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2005533055A (ja) * 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド 新規マキシｋチャンネルブロッカー、その使用方法および製造方法
US8580851B2 (en) * 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
WO2004019938A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
EP2314299A1 (en) * 2002-08-29 2011-04-27 Santen Pharmaceutical Co., Ltd Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin
WO2004037786A2 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. 2-pyrrolidones as ep4 receptor agonists
AU2003280812A1 (en) 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
CA2519899A1 (en) * 2003-03-27 2004-10-14 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2005011704A1 (ja) * 2003-07-31 2005-02-10 Santen Pharmaceutical Co., Ltd. プロスタグランジン含有製品
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
US20080139652A1 (en) 2003-11-07 2008-06-12 Yusuke Sakai Pharmaceutical Composition Containing Prostaglandin
WO2006062184A1 (ja) * 2004-12-09 2006-06-15 Santen Pharmaceutical Co., Ltd. 分子内にフッ素原子を有するプロスタグランジン含有製品
ES2386148T3 (es) * 2004-12-24 2012-08-10 Santen Pharmaceutical Co., Ltd. Productos que contienen un derivado de prostaglandina F2 alfa
EP1830793A1 (en) * 2004-12-29 2007-09-12 R-Tech Ueno, Ltd. Composition and method for scalp and hair treatment
EP1853271B1 (en) * 2005-03-04 2010-12-01 Sucampo AG Method and composition for treating peripheral vascular diseases
JP4648340B2 (ja) * 2006-02-07 2011-03-09 株式会社アールテック・ウエノ １５−ケトプロスタグランジンｅ誘導体の製造法
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
US20090018204A1 (en) * 2007-07-13 2009-01-15 Brinkenhoff Michael C Composition and method for enhancing hair growth
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
EP2288600A1 (en) * 2008-04-24 2011-03-02 Allergan, Inc. Substituted arylcyclopentenes as prostaglandin ep2 agonists
WO2009132088A1 (en) 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8609729B2 (en) 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
NZ628266A (en) 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
BR112013002584A2 (pt) 2010-08-02 2016-06-07 Pharma Patent Holding Inc composição, processo de kit para aperfeiçoamento de cabelo
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
TW201729813A (zh) 2011-02-04 2017-09-01 Kowa Co Ltd 青光眼預防或治療之藥物療法
US8889735B2 (en) 2011-04-07 2014-11-18 Sucampo Ag Method for treating asthenopia
CN103841966A (zh) * 2011-08-05 2014-06-04 苏坎波公司 治疗精神分裂症的方法
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
UA124698C2 (uk) 2014-10-20 2021-11-03 Сентіс Фарма Прайвет Лімітед Офтальмологічний розчин

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1476661A (en) * 1974-05-13 1977-06-16 American Cyanamid Co Prostaglandins
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
EP0242580B1 (en) * 1986-03-13 1993-04-28 The Trustees Of Columbia University In The City Of New York Use of a, b and c prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
US4824857A (en) * 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2038289T3 (es) * 1987-05-15 1993-07-16 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Utilizacion de 15-ceto-pges para la fabricacion de un medicamento para aumentar la temperatura corporal.
JPS6453101A (en) * 1987-05-25 1989-03-01 Kurashiki Boseki Kk Equal tilt angle interference type film thickness gauge
JP2597629B2 (ja) * 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化

Also Published As

Publication number Publication date
GB2209939A (en) 1989-06-01
JP2592204B2 (ja) 1997-03-19
CA1328075C (en) 1994-03-29
EP0308135B1 (en) 1992-11-19
ES2052735T3 (es) 1994-07-16
DE3850676T2 (de) 1994-11-03
EP0308135A2 (en) 1989-03-22
DE3850676D1 (de) 1994-08-18
ATE108330T1 (de) 1994-07-15
JPH0571567B2 (enExample) 1993-10-07
US5001153A (en) 1991-03-19
EP0455264A2 (en) 1991-11-06
GB2209939B (en) 1992-01-02
GR3006319T3 (enExample) 1993-06-21
KR890004707A (ko) 1989-05-09
KR930000051B1 (ko) 1993-01-06
AU600168B2 (en) 1990-08-02
EP0455264A3 (en) 1991-11-27
GB8821104D0 (en) 1988-10-05
JPH0680571A (ja) 1994-03-22
NZ226197A (en) 1992-02-25
AU2231388A (en) 1989-03-23
JPH02108A (ja) 1990-01-05
EP0308135A3 (en) 1989-06-14
DE3876050T2 (de) 1993-03-25
EP0455264B1 (en) 1994-07-13
DE3876050D1 (de) 1992-12-24

Similar Documents

Publication Publication Date Title
ATE82499T1 (de) Okulare hypotensivagenzien.
ATE135699T1 (de) 4,5,6-substituierte 2-pyrimidinamine
MA21216A1 (fr) Compositions de blanchiment.
FI882804L (fi) Oljekompositioner.
DE3883627D1 (de) 1,4-Dihydropyridin-Enantiomere.
ATE61055T1 (de) 1,4-dihydropyridine.
FI853255A0 (fi) Foerfarande foer framstaellning av 6-klor-n-metyl-2,3,4,5-tetrahydro-1h-3-bensazepin.
NO884333D0 (no) 1,4-dihydropyridiner.
DE3779942D1 (de) Schmiermittelzusammensetzungen.
DE69003075D1 (de) Stabilisierungszusammensetzungen.
FI904852A0 (fi) Antikoagulantpeptider.
ZA893346B (en) Anticoagulant peptide alcohols
DE3585873D1 (de) Vinylbenzyl-2,2,6,6-tetramethylpiperidine.
ES2043707T3 (es) 1-sila-2-azaciclopentanos n-silil sustituidos.
FI883266A0 (fi) 4-aminosubstituerade 1,2-dihydronaftalenderivat.
FI883935L (fi) Foerfarande foer framstaellning av 1,6-di (n3-cyano-n1-guanidino) hexan.
FI882805L (fi) Oljekompositioner.
NO883125D0 (no) Beleggsammensetninger for tekstiler.
ATE68486T1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl - 1h-imidazol.
ATE85185T1 (de) 1,4-naphthochinonderivate enthaltende rodentizide zusammensetzungen.
IT8420775V0 (it) Corpo musicale, nonche' di illuminazione, automatico.
DE69018308D1 (de) Antischaum-Zusammensetzungen.
DE3577559D1 (de) 4h-pyrimido(2,1-a)isochinolin-4-onderivate.
DE3777600D1 (de) Substituierte 1,3,4-oxathiazol-2-one-stabilisatoren.
ATE93851T1 (de) 1,4-dihydropyridin-enantiomere.

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time